- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02440672
JOURNEY™ II CR Total Knee System
June 15, 2023 updated by: Smith & Nephew, Inc.
A Prospective, Non-randomized, Single Cohort, Multicenter Study to Evaluate the Clinical Outcomes of Total Knee Arthroplasty (TKA) Using the JOURNEY™ II CR Total Knee System
The purpose of this study is to evaluate the safety and effectiveness of the JOURNEY™ II CR Total Knee System in subjects with degenerative joint disease (DJD) requiring primary total knee replacement.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Detailed Description
This is a prospective, non-randomized, single cohort, multicenter study to evaluate the clinical outcomes of TKA using the JOURNEY™ II CR Total Knee System in subjects with degenerative joint disease (DJD) requiring primary total knee replacement.
One hundred and seventy (170) subjects will be enrolled at up to 18 clinical sites globally.
Follow-up clinical assessments will be performed at 3 months, 1 year, 2 years, 5 years, and 10 years post-operatively.
Study Type
Interventional
Enrollment (Actual)
170
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Barcelona, Spain
- Hospital Parc Taulí Servei de Cirurgia Ortopèdica I Traumatologia
-
-
-
-
-
Stanmore, United Kingdom
- Royal National Orthopaedic Hospital NHS Trust
-
Whitechapel, United Kingdom
- Barts Health NHS Trust
-
-
-
-
Arizona
-
Phoenix, Arizona, United States, 85054
- Orthopedic Institute of the West
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- Rush University Medical Center
-
-
Maryland
-
Annapolis, Maryland, United States, 21401
- Anne Arundel Health System Research Institute, Inc
-
-
New York
-
New York, New York, United States, 10032
- Center for Hip and Knee Replacement at Columbia University Medical Center
-
-
North Carolina
-
Winston-Salem, North Carolina, United States, 27157
- Wake Forest University
-
-
Ohio
-
Cincinnati, Ohio, United States, 45219
- The Lindner Research Center, Musculo-Skeletal Division - The Christ Hospital Health Network
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
22 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
Subjects MUST meet ALL of the following criteria for inclusion in the study:
- Has signed the IRB/EC approved ICF specific to this study prior to study participation
- Is a male or female ≥ 22 and ≤ 75 years of age presenting with degenerative joint disease (DJD) of the knee
Is a candidate for primary total knee arthroplasty with the JOURNEY™ II CR Total Knee System due to DJD, defined by one of the following:
- Post-traumatic arthritis
- Osteoarthritis
- Degenerative arthritis
- Is able to read and understand the approved Informed Consent Form and Patient Reported Outcome (PRO) assessments (written and oral)
- Is in general good health (as determined by the Investigator) based on screening assessments and medical history
- Is independent, ambulatory, and can comply with all post-operative evaluations
- plans to be available through ten (10) years post-operative follow-up
Exclusion Criteria:
- Subjects will be excluded from the study, if they meet ANY one (1) of the following criteria:
Any of the following conditions in the index joint:
- does not require patella resurfacing
- has received a TKA or unicondylar arthroplasty
- has inadequate bone stock to support the device (e.g. severe osteopenia/osteoporosis)
Any of the following conditions in the contralateral joint:
- has enrolled in the study for the contralateral knee
- has received TKA as a revision for a failed total or unicondylar knee arthroplasty
- has received a primary TKA or unicondylar knee arthroplasty that is not fully healed and well-functioning, as determined by Investigator
Any of the following conditions of the hip:
- received contralateral or ipsilateral revision hip arthroplasty
- has ipsilateral hip arthritis resulting in flexion contracture
- has received a ipsilateral or contralateral primary total hip arthroplasty or hip resurfacing arthroplasty, that is not fully healed and well-functioning, as determined by Investigator
- Has diagnosis of an immunosuppressive disorder
- Has presence of malignant tumor, metastatic, or neoplastic disease
- Has family history of severe osteoporosis/osteopenia
- Has a known allergy to study device or one or more of its components
- Has conditions that may interfere with the TKA survival or outcome (e.g. Paget's or Charcot's disease, vascular insufficiency, lupus, muscular atrophy, uncontrolled diabetes, moderate to severe renal insufficiency or neuromuscular disease)
- Is receiving medication for the diagnosis of fibromyalgia
- has a lower extremity condition causing abnormal or restricted ambulation (e.g. ankle fusion, ankle arthroplasty, previous hip fracture)
- Is pregnant or plans to become pregnant during the study
- Has an emotional or neurological condition that would pre-empt their ability or willingness to participate in the study and complete PROs, as determined by Investigator
- Has a BMI>40
- Is currently enrolled in or has participated in another investigational drug, biologic, or device study within 3 months of enrollment
- Is currently involved in personal injury litigation or a worker's compensation claim
- Is facing current or impending incarceration
- Is known to be at risk for lost to follow-up, or failure to return for scheduled visits
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Device:JOURNEY™ II CR Total Knee System (J II CR TKS)
Subjects having TKA with JOURNEY™ II CR Total Knee System
|
TKA with Journey II CR Total Knee System
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Equivalence in 1 year post-operative mean Range of Motion (ROM) in subjects receiving the J II CR TKS as compared to the literature reference mean ROM
Time Frame: 1 year post-op analysis
|
1 year post-op analysis
|
Non-inferiority of the survival rate of the J II CR TKS with the reference survival rate of a literature reference at 5 and 10-years post-operatively
Time Frame: Up to 10 year post-operative analysis
|
Up to 10 year post-operative analysis
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Clinical Outcomes: EuroQol 5D (EQ-5D) scale
Time Frame: Pre-Op to 10 yrs
|
Pre-Op to 10 yrs
|
Clinical Outcomes: 2011 Knee Society Score (2011 KSS) clinical evaluation
Time Frame: Pre-Op to 10 yrs
|
Pre-Op to 10 yrs
|
Clinical Outcomes: Self-Administered Patient Satisfaction Scale for Primary Hip and Knee Arthroplasty (SAPSS
Time Frame: Pre-Op to 10 yrs
|
Pre-Op to 10 yrs
|
Health Economic Endpoints : Physical therapy visit quantification/duration
Time Frame: 30, 60, and 90-day hospital re-admission rate
|
30, 60, and 90-day hospital re-admission rate
|
Health Economic Endpoints: Discharge destination(s)/length of stay
Time Frame: 30, 60, and 90 days
|
30, 60, and 90 days
|
Health Economic Endpoints: Unscheduled professional visits (e.g. hospital, emergency room, orthopedic clinic, primary care physician)
Time Frame: 30, 60, and 90 days
|
30, 60, and 90 days
|
Health Economic Endpoints: Concomitant medications/procedures associated with the knee
Time Frame: 30, 60, and 90 days
|
30, 60, and 90 days
|
Safety Endpoints:Adverse events, to be evaluated by type, frequency, severity, and relatedness to the study treatment.
Time Frame: Pre-Op to 10 yrs
|
Pre-Op to 10 yrs
|
Safety Endpoints: Manipulations under anesthesia
Time Frame: Pre-Op to 10 yrs
|
Pre-Op to 10 yrs
|
Safety Endpoints: Radiographic analysis
Time Frame: Pre-Op to 10 yrs
|
Pre-Op to 10 yrs
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Chair: Rebecca McDonald, Smith & Nephew, Inc.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2015
Primary Completion (Estimated)
December 1, 2026
Study Completion (Estimated)
February 1, 2027
Study Registration Dates
First Submitted
April 28, 2015
First Submitted That Met QC Criteria
May 7, 2015
First Posted (Estimated)
May 12, 2015
Study Record Updates
Last Update Posted (Estimated)
June 16, 2023
Last Update Submitted That Met QC Criteria
June 15, 2023
Last Verified
June 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 13-4049-06
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Osteoarthritis, Knee
-
LifeBridge HealthMicroPort Orthopedics Inc.; Rubin Institute for Advanced OrthopedicsRecruitingKnee Osteoarthritis | Osteoarthritis, Knee | Knee Pain Chronic | Arthropathy of Knee Joint | Knee Disease | Osteoarthritis Knees Both | Osteoarthritis Knee Left | Osteoarthritis Knee RightUnited States
-
University Hospital, Clermont-FerrandSanofiCompletedKnee Osteoarthritis (Knee OA)France
-
Joseph E. BroylesCompletedDegenerative Lesion of Articular Cartilage of Knee | Degeneration; Articular Cartilage, Knee | Unilateral Primary Osteoarthritis of Knee | Osteoarthritis Knee
-
The Hong Kong Polytechnic UniversityCompleted
-
Federal University of São PauloCompletedKNEE OSTEOARTHRITISBrazil
-
Jiangsu XinChen-Techfields Pharma Co., LTD.Completed
-
Tianjin XinChen-Techfields Pharma Co., LTD.Completed
-
Eun Jung KimMinistry of Health & Welfare, Korea; Semyung UniversityUnknownOsteoarthritis KneeKorea, Republic of
-
Thammasat UniversityCompletedPrimary Knee OsteoarthritisThailand
-
Galderma R&DCompletedUnilateral Knee OsteoarthritisUnited Kingdom
Clinical Trials on JOURNEY™ II CR Total Knee System (J II CR TKS)
-
Smith & Nephew, Inc.WithdrawnArthroplasty | Knee | ReplacementSingapore, China, India
-
Smith & Nephew, Inc.Nor ConsultCompletedJourney II CR Total Knee SystemUnited States
-
St. Olavs HospitalSmith & Nephew, Inc.Not yet recruitingArthroplasty | Arthritis Knee | Gait AnalysisNorway
-
Smith & Nephew Pte LtdActive, not recruitingNon-inflammatory Degenerative Joint DiseaseIndia, Korea, Republic of, Italy, South Africa
-
Smith & Nephew, Inc.Active, not recruitingOsteoarthritis, KneeUnited States
-
Smith & Nephew, Inc.CompletedTotal Knee ArthroplastyUnited States, Belgium, Switzerland
-
The University of Tennessee, KnoxvilleSmith & Nephew, Inc.CompletedOsteoarthritis, Knee | Arthroplasty, Replacement, KneeUnited States
-
Smith & Nephew, Inc.Active, not recruitingKnee Osteoarthritis | Rheumatoid Vasculitis With Rheumatoid Arthritis of Knee | Unilateral Post-Traumatic Osteoarthritis of Knee | Degenerative Arthritis Peripheral Joint | Failed Osteotomies | Failed Unicompartmental ReplacementUnited States
-
Smith & Nephew, Inc.CompletedJourney II BCS Total Knee SystemUnited States, Belgium, New Zealand
-
Smith & Nephew, Inc.Active, not recruitingNon-inflammatory Degenerative Joint Disease (NIDJD) of the KneeUnited States, Italy, Poland